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Objective: To describe the association between obesity and the use of antipsychotic drugs 
(APDs) in adult outpatients followed-up on in ﬁ  ve Primary Care settings.
Methods: A longitudinal, retrospective design study carried out between July 2004 and June 
2005, in patients who were included in a claim database and for whom an APD treatment 
had been registered. A body mass index (BMI)  30 kg/m2 was deﬁ  ned as obesity. The main 
measurements were: use of APDs, demographics, medical background and co-morbidities, and 
clinical parameters. Logistic regression analysis and ANCOVA with Bonferroni adjustment 
were applied to correct the model.
Results: A total of 42,437 subjects (mean age: 50.8 (18.4) years; women: 54.5%; obesity: 
27.3% [95% conﬁ  dence intervals (CI), 26.9%–27.7%]) were analyzed. A total of 1.3% of the 
patients were receiving APDs, without statistical differences in distribution by type of drug 
(typical: 48.8%; atypical: 51.2%). Obesity was associated with the use of APDs [OR = 1.5 
(CI: 1.3–1.8)], hypertension [OR = 2.4 (CI: 2.2–2.5)], diabetes [OR = 1.4 (CI: 1.3–1.5)] and 
dyslipidemia [OR = 1.3 (CI: 1.2–1.4)], p   0.0001 in all cases. BMI was signiﬁ  cantly higher 
in subjects on APDs; 28.8 vs. 27.3 kg/m2, p = 0.002, and remained higher after adjusting by 
age and sex (mean difference 0.4 (CI: 0.1–0.7), p   0.01). After adjusting by age, sex and 
the Charlson index, obese subjects generated higher average annual total costs than nonobese 
subjects;  811 (CI: 787–835) vs.  694 (CI: 679–709), respectively, p   0.001.
Conclusions: Obesity was associated with the use of APDs, regardless of the type of drug, 
and with the presence of hypertension, diabetes and dyslipidemia. Obesity was also associated 
with substantially higher health care costs.
Keywords: Obesity, claim database, retrospective study, antipsychotic use, Primary Care set-
ting, resources utilization, health care costs
Introduction
Metabolic disorders such as obesity, diabetes or dyslipidemia increase the risk of 
cardiovascular events (Guallar-Castillón et al 2002). Speciﬁ  cally, obesity exerts an 
unquestionable impact on population health, due to its high associated morbidity-
mortality (Guallar-Castillón et al 2002; Mackin et al 2005). Its prevalence in the general 
population ranges between 6% and 20% (The Netherlands, USA), with an increased 
presence in females and a trend to increase with age, reaching a peak in the decade of 
40–50 years. In Spain, the data provided by the Spanish Society for Study of Obesity 
(SEEDO) (Aranceta-Bartrina et al 2005), and also reported by different studies, indicate 
percentages in excess of 14%, with a clear tendency to gradually increase in the future 
(Aranceta-Bartrina et al 2005; Gutiérrez-Fisac et al 2005).Neuropsychiatric Disease and Treatment 2008:4(1) 220
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On the other hand, the use of antipsychotic drugs (APDs) 
has been increasing considerably during recent years, not 
only as a result of growth in the population that uses such 
substances, but also because of expanded use of such medica-
tion in other clinical situations in which they are considered 
to be of potential beneﬁ  t for patients. However, the evidence 
to date suggests that antipsychotics, or at least some of the 
most widely used APDs, are associated with a considerable 
increase in patient body weight ( 7%) and with the develop-
ment of glucose and lipid metabolic alterations. This in turn 
can imply an increased risk of premature death among such 
patients due to cardiovascular events (Haupt 2006; Tandon 
et al 2006; Wu et al 2006). These repercussions are more 
notorious in the case of second generation APDs (atypical 
drugs), though the level of risk tends to vary according to the 
different drug substances used (Babidge et al 2001; Morgan 
et al 2003; Hiroeh et al 2001). These drugs increase the 
activity of AMP kinase within the hypothalamus, blocking 
the activity of the H1 histamine receptors. In this way, a link 
is established between weight gain and atypical APD use. 
Although the typical or classical APDs also induce this side 
effect, the precise mechanism involved in this case is not 
known (Haupt 2006). Nevertheless, considerable controversy 
is found among different authors. As an example, clozapine 
and olanzapine, in addition to the known increases in body 
weight, can also elevate cholesterol and triglyceride con-
centrations (ADA et al 2004; Kane et al 2004; Fenton et al 
2006; Pujol-Domenech et al 2006), or increase the risk of 
developing diabetes mellitus (Aranceta-Bartrina et al 2005; 
Flores-Meneses et al 2005). Similar results have also been 
recorded in patients treated with risperidone, though the nega-
tive effects upon the health of these subjects are somewhat 
more controversial. Unfortunately, the role and importance 
of each of them are often difﬁ  cult to assess, and it is likewise 
difﬁ  cult to determine whether certain biological alterations 
are the cause or effect of the excess body weight (Jin et al 
2004; Dinca et al 2005; Flores-Meneses et al 2005; Haupt 
2006; Pujol-Domenech et al 2006; Schneider et al 2006; 
Woodward et al 2007).
The present study further evaluates previously observed 
associations between obesity and typical and atypical APD 
use, and explores its inﬂ  uence upon health care resource 
utilization in adult outpatients followed-up on by ﬁ  ve primary 
care teams in the Spanish population setting.
Methods
A retrospective, multicenter study was conducted based on the 
medical records of adult patients monitored on an outpatient 
basis and under normal clinical practice conditions. The study 
population was seen by ﬁ  ve Primary Care teams managed 
by Badalona Serveis Assistencials, S.A., and involving a 
designated recruitment population of about 105,300 inhabit-
ants (14.5% over 64 years of age). The designated population 
is predominantly urban, with middle to low socioeconomic 
level, and working mainly in the industrial setting. Primary 
care team organization is of a reformed character, involving 
public management and the provision of private services 
(concerted). Badalona Serveis Assistencials S.A. possesses 
personnel, a training policy, organization model and services 
offered proﬁ  le similar to that of most primary care centers in 
Catalonia, Spain, with decentralized management and single 
structural services.
The study included all patients seen between July 1, 
2004 and June 30, 2005, meeting the following criteria: a) 
age over 18 years; b) initiation of pharmacological treatment 
with APDs; and c) inclusion in the chronic prescriptions 
program with regular patient reports for the programmed 
visits to obtain the corresponding medical prescriptions 
(with registry of the daily dose, time interval and duration 
of each treatment). Patients failing to report to the centers 
were excluded, as were those displaced or outside the zone, 
and those presenting disabling mental disorders. Obesity was 
deﬁ  ned as the presence of excess body weight secondary to 
the accumulation of adipose tissue, with a body mass index 
(BMI, kg/m2) of over 30 (NCEP 2002). Information was col-
lected on the prescription of APDs (atypical: amisulpiride, 
clozapine, olanzapine, quetiapine, risperidone and zipra-
sidone; typical: chlorpromazine, clotiapine, ﬂ  uphenazine, 
haloperidol, levomepromazine, perphenazine, periciazine, 
pimozide, pipothiazine, tiapride, thioproperazine, thiorida-
zine, zuclopentixol), reﬂ  ected in the computer-based case 
histories, according to the recommendations of the pre-
scribing physician (WHO 1995). Quantiﬁ  cation was made 
of the number of health problems attended per patient/year 
(comorbidity), considered as a diagnosis-equivalent disease 
care problem (International Classiﬁ  cation of Primary Care, 
ICPC) (Lamberts et al 1993). The personal antecedents 
were the following: arterial hypertension (K86), dyslipid-
emia (T93), diabetes mellitus (T90), active smoking (P17), 
alcoholism (P15), ischemic heart disease (K74, cardiac isch-
emia with angina; K75, acute myocardial infarction; K76, 
coronary ischemia), cerebrovascular accident (K90, K91), 
cardiovascular event, chronic obstructive pulmonary disease 
(R95, chronic airﬂ  ow obstruction) and bronchial asthma 
(R96). The Charlson Index was quantiﬁ  ed as an estimation 
of morbidity burden (severity), and the following clinical Neuropsychiatric Disease and Treatment 2008:4(1) 221
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parameters were documented (medical records): systolic 
blood pressure (SBP, mmHg) and diastolic blood pressure 
(DBP, mmHg), baseline blood glucose (mg/dl), triglycerides 
(mg/dl), total cholesterol (mg/dl), low density lipoprotein 
cholesterol (LDL-c, Friedewald in mg/dl) and high density 
lipoprotein cholesterol (HDLc) in mg/dl.
The consumed health care resources, documented from 
the registries of each center, comprised the visits or appoint-
ments with the Primary Care center, referrals to the reference 
specialists, requests for supporting complementary tests, 
and drug prescriptions charged to CatSalut occurring during 
the study period of evaluation. Visits made were deﬁ  ned as 
appointments programmed between the professional team and 
the patient due to a health demand or problem, in the center 
or in the home of the patient. The design of the costs system 
was deﬁ  ned taking into account the characteristics of the 
organization and the degree of development of the available 
information systems. The unit health care product serving 
as basis for ﬁ  nal calculation was the cost/patient attended 
during the study period. According to dependence on the 
volume of activity carried out, consideration was made of 
the ﬁ  xed/semi-ﬁ  xed costs (with imputation criteria) and the 
variable costs. Fixed/semi-ﬁ  xed costs (structure) were taken 
to be those relating to personnel (fees and salaries), consumer 
goods, and a series of expenses pertaining to external services, 
in accordance with the General Accounting Plan for Health 
Care Centers, while variable costs were taken to be those 
related to diagnostic or therapeutic requests, or referrals 
decided by the professionals of the center. The different study 
concepts and their economical assessment were the following: 
a) complementary tests, including laboratory tests (mean cost 
per request), conventional radiology (fee per requested test), 
and supporting tests (fee per requested test); b) referrals to 
reference specialists or to hospital centers on an ordinary or 
emergency basis (adjusted fee per referral); and c) prescrip-
tions (medical prescriptions on an acute or chronic basis, 
or upon demand; public sales price per container). The fees 
used were obtained from analytical accountancy studies made 
within the organization itself, or from prices as established by 
CatSalut (Garcia-Cardona et al 1995; Orden de la Generalitat 
de Catalunya 1995). Based on the semi-ﬁ  xed costs, a mean 
cost per visit made was obtained, and a ﬁ  nal direct distribu-
tion was carried out for each patient attended during the study 
period. Thus, the cost per patient (Cp) was: Cp = (mean cost 
per visit x number of visits [semi-ﬁ  xed costs]) + variable 
costs. As a step prior to analysis, and in particular to the 
information source pertaining to the case histories retrospec-
tive claim database (OMIAP), a careful review was made of 
the data, in search of possible registry or coding errors. Data 
quality was considered adequate, and the data were obtained 
on a computerized basis, with due observation of the legal 
regulations on information conﬁ  dentiality.
A statistical analysis was made, with calculation of the 
mean and standard deviation (SD), and corresponding 95% 
conﬁ  dence intervals (CI). Parametric tests (chi-square and 
Student t-test) were used for the relationship between vari-
ables in the bivariate analysis. A logistic regression analysis 
(forward step procedure) was performed to correct the model, 
including the variables according to signiﬁ  cance of the results 
in the bivariate analysis and their clinical signiﬁ  cance (depen-
dent variable: obesity). Comparison of ambulatory cost was 
made following the recommendations of Thompson and 
Barber (2000) based on analysis of covariance (ANCOVA) 
with patient sex, age, and number of co-morbidities as covari-
ates (estimation of marginal means; Bonferroni correction). 
The SPSSWIN version 12 statistical package was used, 
accepting statistical signiﬁ  cance for p   0.05.
Results
Information was obtained on 42,437 patients (Table 1), with 
a mean age of 50.8 (18.4) years (54.5% females). The mean 
number of visits/year was 10.0 (9.0), with a mean number 
of episodes/year of 5.9 (3.8), and a mean Charlson Index of 
0.4 (0.6). According to the NCEP-ATP III, 27.3% (95% CI: 
26.9%–27.7%) of the population attended met criteria of 
obesity (BMI = 27.4 kg/m2), while 1.3% (CI: 1.2%–1.4%) 
were receiving treatment with APDs – fundamentally 
olanzapine (23.3%), risperidone (22.1%) and haloperidol 
(11.3%). The main reason for using antipsychotics were dis-
orders of the schizophrenia spectrum [254 (46.1%)], bipolar 
disorders [95 (17.3%)], dementia and other cognitive deﬁ  cits 
[71 (12.8%)], restlessness [41 (7.5%)], anxiety [25 (4.5%)], 
organic psychoses [24 (4.4%)], and others [41 (7.4%)].
The proportion of individuals receiving treatment with 
APDs was signiﬁ  cantly greater among the obese patients: 
1.8% vs. 1.1%, p   0.0001, though there were no differ-
ences in proportion between conventional and atypical 
drugs: 48.8% vs. 51.2%, respectively, or in terms of the drug 
substance involved (Table 1). Obesity was associated with 
the majority of the general variables, co-morbidities and 
clinical parameters studied. A greater mean age of 57.9 (15.5) 
years vs. 48.2 (18.8) years, with a predominance of females 
59.9% vs. 52.4%, and a greater number of visits 12.1 (9.8) 
vs. 9.1 (8.5) and episodes 7.0 (4.0) vs. 5.4 (3.6), respectively 
(p   0.001) was seen in all cases. In these patients, a larger 
proportion of modiﬁ  able cardiovascular risk antecedents Neuropsychiatric Disease and Treatment 2008:4(1) 222
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was observed: arterial hypertension 47.0% vs. 19.9%, 
dyslipidemia 35.9% vs. 22.6%, diabetes mellitus 19.0% vs. 
9.0%; and cardiovascular events 9.2% vs. 6.3%, respectively, 
p   0.001. The clinical parameters, systolic blood pressure: 
135.2 (16.1) vs. 127.0 (16.6) mmHg; triglycerides: 140.6 
(89.7) vs. 112.3 (75.2) mg/dl; total cholesterol: 221.4 (42.3) 
vs. 204.9 (45.3) mg/dl, and baseline blood glucose: 106.6 
(32.8) vs. 95.1 (25.5) mg/dl, respectively (p = 0.001), in all 
cases (Table 1). BMI was signiﬁ  cantly higher in subjects 
on APDs: 28.8 vs. 27.3 kg/m2, p = 0.002, and remained 
higher after adjusting by age and sex: mean difference of 
0.4 (0.1-0.7, p   0.01).
In the ﬁ  nal logistic model (Table 2), corrected for age 
and sex, obesity was seen to be associated with APD use 
(OR = 1.5 [CI: 1.3–1.8]), hypertension (OR = 2.4 [CI: 
2.2–2.5]), diabetes (OR = 1.4 [CI: 1.3–1.5]) and dyslipidemia 
(OR = 1.3 [CI: 1.2–1.4]), p   0.001. Patient age and sex were 
likewise signiﬁ  cantly associated to the presence of obesity; 
the male sex was associated with a 20%–30% lesser prob-
ability of being obese (p   0.0001), while a one-year increase 
in age was associated to a 10%–30% increase in the risk of 
obesity (p   0.0001). The general characteristics and clinical 
parameters of the patients according to APD use versus the 
control group are reported in Table 3. These subjects show 
a greater mean age of 56.4 (19.5) vs. 50.7 (18.4) years, BMI 
28.8 (5.7) vs. 27.3 (5.1) kg/m2, noticeably higher baseline 
blood glucose and triglyceride levels, and lower HDLc 
concentrations, respectively (p   0.001), in all cases.
Table 1 General characteristics of the study sample in the absence or presence of obesity
Study variables Nonobese (n = 30,843) Obese (n = 11,594) Total (n = 42,437) P
Subjects treated with APDs (%) n = 344 (1.1%) n = 207 (1.8%) n = 551 (1.3%)  0.0001
General
Mean age (SD), years 48.2 (18.8) 57.9 (15.5) 50.8 (18.4)  0.0001
Sex (females) 52.4 59.9 54.5  0.0001
Mean visits/year 9.1 (8.5) 12.1 (9.8) 10.0 (9.0)  0.0001
Body mass index (SD), kg/m2 25.0 (3.0) 33.8 (3.6) 27.4 (5.1)  0.0001
Mean episodes/year 5.4 (3.6) 7.0 (4.0) 5.9 (3.8)  0.0001
Mean Charlson Index 0.3 (0.6) 0.5 (0.7) 0.4 (0.6)  0.0001
Antecedents or associated comorbidities
Arterial hypertension 19.9 47.0 27.3  0.0001
Dyslipidemia 22.6 35.9 26.3  0.0001
Diabetes mellitus 9.0 19.0 11.7  0.0001
Smokers 29.2 18.5 26.3  0.0001
Ischemic heart disease 3.5 6.2 4.3  0.0001
Stroke 2.0 2.3 2.1 0.042
Cardiovascular events 6.3 9.2 7.1  0.0001
Alcoholism 1.9 1.7 1.8 NS
Chronic obstructive pulmonary disease 2.9 4.5 3.4  0.0001
Bronchial asthma 3.8 4.7 4.1  0.0001
Clinical parameters
Systolic blood pressure (SD), mmHg 127.0 (16.6) 135.2 (16.1) 129.6 (16.9)  0.0001
Diastolic blood pressure (SD), mmHg 75.1 (9.5) 79.5 (9.4) 76.5 (9.7)  0.0001
Baseline blood glucose (SD), mg/dl 95.1 (25.5) 106.6 (32.8) 98.5 (28.4)  0.0001
Serum triglycerides (SD), mg/dl 112.3 (75.2) 140.6 (89.7) 121.5 (81.3)  0.0001
Total cholesterol (SD), mg/dl 204.9 (45.3) 221.4 (42.3) 217.7 (43.6)  0.0001
HDL-cholesterol (SD), mg/dl 48.3 (13.7) 44.0 (12.0) 46.9 (13.3)  0.0001
LDL-cholesterol (SD), mg/dl 138.0 (36.1) 143.1 (34.3) 139.6 (35.6)  0.0001
Notes: Values are given as percentage or mean.
Abbreviations: SD, standard deviation; p, statistical signiﬁ  cance; NS, nonsigniﬁ  cant; APD, antipsychotic drug; HDL-cholesterol, high density lipoprotein cholesterol; LDL-
cholesterol, low density lipoprotein cholesterol.Neuropsychiatric Disease and Treatment 2008:4(1) 223
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The total direct costs in Primary Care of the attended 
patients were 27.7 million euros, with a distribution of 
27.1% corresponding to ﬁ  xed or semi-ﬁ  xed costs, and the 
rest to variable costs. In this context, referrals to reference 
specialists stood out (8.0%), along with pharmaceutical 
prescription: 59.4% (Table 4). This table reports the total 
costs and the costs by components; uncorrected observed 
costs and differential costs corrected for morbidity burden, 
age and sex among the patients with obesity (versus the 
nonobese control population). The obese individuals were 
associated with signiﬁ  cantly greater corrected total costs of 
811 (CI:  787–835) vs.  694 (CI:  679–709), respec-
tively, p   0.001. All the components of the corrected costs 
were signiﬁ  cantly greater in the presence of obesity.
Discussion
The results of this study show obese patients seen in the Pri-
mary Care setting to represent 27.3% of the total. Compared 
with the general population, this markedly high percentage 
can be explained in part by the fact that the attended patients 
are not representative of the general population, and because 
young individuals less commonly resort to health care 
services. Nevertheless, the lack of knowledge of the speciﬁ  c 
etiology of the disorder and the scant therapeutic resources 
available, lead to a limited percentage treatment success 
that is often followed by recovery of the initial body weight. 
The above suggests that treatment and preventive activities 
targeting obesity are inefﬁ  cient in the Primary Care setting. 
This in turn generates a certain relaxed approach to this risk 
factor, and a reluctance to dedicate major efforts to solve 
the problem – in contrast to other disorders which are more 
amenable to effective medical intervention.
In the logistic model, obesity was associated with the 
use of APDs and the presence of hypertension, diabetes and 
dyslipidemia, and with patient age and sex. These results 
are similar to those reported in the consulted literature 
(Aranceta-Bartrina et al 2005; Gutiérrez-Fisac et al 2005; 
Haupt 2006; Mackin et al 2005; Tandon et al 2006), though 
the impact of obesity upon health requires the adoption of a 
preventive approach that can only be achieved through the 
generalization of educative and preventive activities (Haupt 
2006). These data reﬂ  ect the importance of preventing weight 
gain in such patients, with adequate treatment in each case, 
and posterior supervision of the patients that receive APD 
therapy – particularly among those presenting a high cardio-
vascular risk or those who are already obese (Haupt 2006; 
Wu et al 2006). No differences were observed between the 
uses of conventional or atypical APDs in relation to obesity. 
This may be due to patient selection bias, a statistical artifact, 
or limited statistical power as a result of the small number of 
patients in each group (Flores-Meneses et al 2005). Likewise, 
the possibility that a modiﬁ  cation in APD treatment regimen 
may have altered our ﬁ  ndings cannot be ruled out.
Table 2 Results of the logistic regression model with obesity as 
dependent variable
Variables of the model Beta p OR 95%CI
Antipsychotics use 0.421  0.0001 1.5 1.3 – 1.8
Age (years) 0.132  0.0001 1.2 1.1 – 1.3
Sex (male) −0.272  0.0001 0.8 0.7 – 0.8
Arterial hypertension 0.864  0.0001 2.4 2.2 – 2.5
Diabetes mellitus 0.323  0.0001 1.4 1.3 – 1.5
Dyslipidemia 0.272  0.0001 1.3 1.2 – 1.4
Abbreviations: OR, odds ratio; CI, 95% conﬁ  dence interval.
Table 3 Overall characteristics and clinical parameters of the 
patients included in the study according to the use of antipsy-
chotic drugs (APDs)






Sex (females) 54.5% 56.4% NS
Mean age (SD), years 50.7 (18.4) 56.4 (19.5)  0.0001
Body Mass Index (SD), 
kg/m2
27.3 (5.1) 28.8 (5.7)  0.0001
Mean visits/year (SD) 9.8 (8.9) 14.8 (11.3)  0.0001
Mean episodes/year (SD) 5.9 (3.8) 7.1 (4.3)  0.0001
Mean Charlson Index 
(SD)
0.3 (0.6) 0.5 (0.7)  0.0001
Clinical parameters
Systolic blood pressure 
(SD), mmHg
129.6 (16.9) 128.2 (15.8) NS
Diastolic blood pressure 
(SD), mmHg
76.5 (9.7) 75.9 (9.4) NS
Baseline blood glucose 
(SD), mg/dl
98.4 (28.3) 102.1 (35.0) 0.006
Serum triglycerides (SD), 
mg/dl
121.2 (81.1) 139.6 (90.5)  0.0001
Total cholesterol (SD), 
mg/dl
206.8 (41.5) 207.9 (42.2) NS
HDL-cholesterol (SD), 
mg/dl
46.9 (13.3) 43.6 (12.6)  0.0001
LDL-cholesterol (SD), 
mg/dl
139.6 (35.6) 139.8 (34.5) NS
Notes: values are given as percentage or mean.
Abbreviations: SD, standard deviation; NS, nonsigniﬁ  cant; HDL-cholesterol, 
high density lipoprotein cholesterol; LDL-cholesterol, low density lipoprotein 
cholesterol.Neuropsychiatric Disease and Treatment 2008:4(1) 224
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In studies of the use of psychoactive drugs, and in 
coincidence with our own observations, a larger proportion of 
treatments were seen to correspond to women – this possibly 
being due to the greater tendency among women to visit 
Primary Care centers (Ustun 1999; Vedia et al 2005). If the 
behavioral pattern among males is changing, then this discrep-
ancy between the costs of males and females could decrease 
over time. It therefore would be interesting to conduct similar 
studies in the future, to conﬁ  rm this possibility. A relevant 
observation in our study is that patients show increased 
health care resource consumption at all levels, regardless of 
age, sex or morbidity – thus resulting in an increased cost 
per patient per year. The largest difference in this sense cor-
responds to pharmacological expenditure. This cost could 
be due to the greater number of drug substances consumed, 
though it cannot be ruled out that part of the difference may 
be attributable to a greater purchasing cost for psychoactive 
medicines, or to the possibility that patients of this kind are 
prescribed latest-generation (and more expensive) drugs for 
the treatment of other mental problems. The second most 
important cost component corresponded to medical visits in 
the Primary Care setting. This coincides with the literature, 
where in general psychiatric patients are seen to seek care 
more often, and do so more in Primary Care centers than in 
psychiatric clinics (Kokkinos et al 2005). In this context, in 
a study of the epidemiology and use of health care resources 
related to mental health in Primary Care, reported that these 
patients present higher consulting rates than those individu-
als without mental disease (Vázquez et al 1997). The highest 
consulting rates were likewise associated with the demo-
graphic variables of patient sex (female) and age.
The results obtained can be explained not only by the 
different geographical composition of the study sample 
(a factor clearly associated to patient age), but also by other 
differences implicated in the studies consulted, and which 
could be explained in part by different health or dietary 
habits (Katerndahl 1995; Gómez et al 2005). Particularly 
as relates to obesity, the question emerges as to what 
other factors could be playing a relevant role in the fact 
that metabolic syndrome is more prevalent among these 
patients. In this context, unhealthy living habits could play 
an important role. In this sense, the role of diet seems to 
be conﬁ  rmed, in view of the observed high prevalence of 
obesity, dyslipidemia, and hypertriglyceridemia. These 
observations, attributable to diet, lifestyle, or other con-
ditioning factors, appear to coincide with the tendency of 
schizophrenic patients to accumulate fat and intraabdominal 
adipose tissue (Hagg et al 2006).
Regardless of the effect of lifestyle and health-damaging 
habits, attention should also focus on the role of the APDs 
used as treatment – some of which have been shown to 
exert a direct inﬂ  uence upon weight gain and lipid and 
carbohydrate metabolic disorders (Ryan et al 2002; Barnett 
et al 2006). Although controversy exists surrounding this, 
such substances could be making an important contribution 
to the appearance of metabolic disorders with an increased 
risk of cardiovascular disease. Other possible causes, such 
as certain alterations of the hypothalamic-pituitary-adrenal 
neuroendocrine axis inducing increased blood cortisol levels 
with genotypic expression in the form of abdominal obesity 
among patients receiving APDs, or the possible effects upon 
hippocampal volume, are aspects requiring further study 
and conﬁ  rmation as potential cardiovascular risk factors in 
patients of this kind (McIntyre et al 2001).
Other limitations require caution in generalizing the 
results, including the inherent observational design of the 
Table 4 General and unit distribution of the model of costs per patient per year (in euros), in the absence or presence of obesity
Nonobese (n = 30.843) Obese subjects (n = 11.594)







Total cost in PC 27,696,430 638 (1.245) 694 [679–709] 981 (1.467) 811 [787–835] 735 (1.320)  0.0001
Fixed/semiﬁ  xed cost 7,511,580 (27%) 182 (170) 192 [190–194] 242 (196) 212 [209–215] 199 (180)  0.0001
Variable cost 20,184,850 (73%) 455 (1.182) 502 [488–516] 739 (1.395) 599 [575–622] 535 (1.253)  0.0001
Cost of referrals 2,211,296 (8%) 54 (76) 56 [55–57] 70 (86) 64 [62–65] 59 (79)  0.0001
Pharmaceutical cost 16,460,466 (59%) 363 (673) 407 [400–414] 624 (807) 497 [485–510] 437 (723)  0.0001
Notes: Values are given as percentage or mean; costs in euros ( ); *adjusted p level; each F-test contrasts the simple effect of obesity in each combination of levels of the 
rest of effects shown. These contrasts are based on comparisons by pairs (linearly independent), between the estimated marginal means. The co-variables appearing in the 
model are evaluated in the following values: Charlson Index = 0.35, mean age = 52.2. Method: Bonferroni correction.
Abbreviations: SD, standard deviation and 95% conﬁ  dence interval; PC, Primary Care.Neuropsychiatric Disease and Treatment 2008:4(1) 225
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study (data underestimation), the possible variability among 
professionals in the different centers, the coordination of 
levels (health care continuum), and the lack of prescribed 
dose adjustment (Tandon et al 2006). Nevertheless, such 
reformed centers present a very similar intervention orga-
nizational and protocol model – thus ensuring a common 
and homogeneous health care level. In future, new studies 
will be needed to conﬁ  rm the consistency of the results 
obtained, and to evaluate strategies designed to reduce 
the cardiovascular risk factors. Likewise, it is important 
to continue advancing in treatment compliance and the 
achievement of objectives, in order to ensure more cost-
effective interventions (Tandon et al 2006).
In conclusion, obesity is an important cardiovascular 
risk factor signiﬁ  cantly associated with the use of APDs 
in the presence of hypertension, diabetes and dyslipid-
emia, and with patient age and sex as nonmodiﬁ  able fac-
tors, leading to an increased consumption of health care 
resources. In our sample, no differences were recorded 
between the uses of conventional or atypical APDs, 
though further research under normal clinical practice 
conditions will be needed to reinforce the consistency of 
these results.
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